Equities

Observe Medical ASA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Observe Medical ASA

Actions
Health CareMedical Equipment and Services
  • Price (NOK)0.825
  • Today's Change-0.135 / -14.06%
  • Shares traded3.60m
  • 1 Year change-80.53%
  • Beta1.2805
Data delayed at least 15 minutes, as of Feb 12 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Observe Medical ASA is a Norway-based medtech company that develops, markets and sells medtech products for the global market. The Company has a broad distribution portfolio of medtech devices and disposables, mainly within Urine measurement, Anesthesiology/ICUs and wound care. The Company is recognized for development and distribution of the Sippi automated digital urine system. Sippi is consist of several products like urine temperature catheters fixating devices to use in combination with urine catheters. Another product Biim is s approved for ultrasound imaging of the human body and is specifically used to guide needle and catheter insertions for dialysis and vascular access procedures. Observe Medical ASA is the parent company of its wholly owned subsidiaries, Observe Medical International AS, Observe Medical AB, Observe Medical ApS, Observe Medical Nordic AB and Biim Ultrasound AS.

  • Revenue in NOK (TTM)16.75m
  • Net income in NOK-123.50m
  • Incorporated2019
  • Employees4.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kontigo Care AB31.12m-2.22m62.51m10.00--1.1616.172.01-0.0589-0.05890.82621.430.4487--7.97---3.190.296-3.980.4064125.51129.99-7.120.4638----0.00---3.667.41-367.61--17.15--
Neola Medical AB0.00-11.74m64.95m8.00--0.7749-----0.1479-0.14790.001.010.00----0.00-13.81-15.62-14.65-16.86--5,384.30---6,523.935.61--0.00-------11.70--35.63--
Episurf Medical AB17.20m-62.06m67.00m18.00--1.32--3.90-0.0533-0.05330.01380.02860.2043--4.54894,444.40-72.97-47.42-86.27-52.18-----357.14-701.121.41-579.000.0935--22.9018.1323.42--7.81--
Redsense Medical AB (publ)32.76m322.59k77.99m4.00221.672.03123.552.380.020.021.862.180.76971.966.616,134,600.000.7578-14.280.8514-15.8661.4568.850.9846-32.794.69--0.00--12.8516.26107.58---53.01--
Scandinavian ChemoTech AB12.47m-9.29m81.10m1.00--13.19--6.50-0.3727-0.37270.50030.26530.7270.59172.661,946,333.00-54.15-92.70-83.07-131.4682.15104.65-74.49-866.060.861-5.610.00--132.6763.8534.96---59.68--
BibbInstruments AB159.16k-14.20m95.30m4.00--2.09--598.79-0.3802-0.38020.00411.050.00382.062.7137,250.00-33.98-36.85-35.53-40.0630.8759.14-8,922.82-22,555.646.67--0.00-------15.85---1.52--
SyntheticMR AB (publ)60.94m-58.67m104.01m41.00--0.6599--1.71-0.9057-0.90570.94671.650.3678--0.87331,391,415.00-35.42-7.92-51.34-10.5110.4156.07-96.28-14.37---8.730.0450--2.473.20-241.50--7.37--
Iconovo AB1.70m-44.04m106.84m19.00--0.4222--63.03-1.67-1.670.05372.460.0117--0.260863,475.20-30.39-28.39-33.14-31.51901.69159.24-2,598.41-295.86---138.020.0391---58.55-24.2210.36--22.28--
Arcoma AB142.00m4.65m108.21m31.0022.091.388.740.7620.32050.32059.875.131.452.9213.714,288,452.004.752.166.663.7540.4537.953.271.402.04--0.000.00-3.813.24336.0011.08-9.43--
Observe Medical ASA16.75m-123.50m112.32m4.00--4.32--6.70-26.57-26.573.290.19090.11182.878.293,350,800.00-82.38-42.22-205.00-64.146.2430.17-737.14-327.970.1175-3.720.9572---33.85153.47-98.73---2.97--
Immunovia AB (publ)838.52k-134.07m129.33m9.00------154.24-0.3569-0.35690.0024-0.0210.0156--0.26487,222.22-249.16-48.08-827.53-52.27-7,231.59-6,932.30-15,989.68-17,625.510.6282-3.001.68---40.8921.2075.26------
Bioretec Oy-1.13tn-1.13tn145.37m57.00---------------------------57.56---77.31--70.90---128.20--------16.3221.07-21.78------
Scandinavian Real Heart AB0.00-41.52m148.44m12.00--0.8326-----16.17-16.170.0016.690.00----0.00-44.53-27.49-52.77-30.65-------12,518.77----0.0678------49.47--6.59--
Ortivus AB81.09m-26.42m149.07m34.00------1.84-0.5583-0.55831.71-0.50621.186.7716.222,372,281.00-38.46-4.62-147.30-8.6534.7941.27-32.59-3.550.4719-4.011.72---4.369.60-36.49--65.37--
iZafe Group AB6.30m-18.94m155.79m10.00--8.86--24.72-0.0614-0.06140.01940.04520.17573.448.15843,000.00-52.78-57.76-73.42-72.44-106.29-287.24-300.41-630.900.9122-17.450.0198--336.55-11.1036.26---24.50--
Scandinavian Medical Solutions A/S372.05m39.41k157.22m28.005,651.521.2511.850.42260.00070.00078.882.991.291.9411.19--0.01376.590.024611.6823.1224.880.01064.680.35241.140.4345--8.2842.38-99.67-64.34----
Data as of Feb 12 2026. Currency figures normalised to Observe Medical ASA's reporting currency: Norwegian Krone NOK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.